Pamela J Russell

List of Publications by Year
in descending order

209 papers	8,914 citations	36203 51 h-index	58464 82 g-index
212 all docs	212 docs citations	212 times ranked	11221 citing authors

#	Article	IF	Citations
1	Large-scale delineation of secreted protein biomarkers overexpressed in cancer tissue and serum. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 3410-3415.	3.3	425
2	Biology and Management of Bladder Cancer. New England Journal of Medicine, 1990, 322, 1129-1138.	13.9	410
3	Genome-wide synteny through highly sensitive sequence alignment: <i>Satsuma</i>. Bioinformatics, 2010, 26, 1145-1151.	1.8	258
4	Detailed methylation analysis of the glutathione S-transferase Ï€ (GSTP1) gene in prostate cancer. Oncogene, 1999, 18, 1313-1324.	2.6	211
5	Growth factor involvement in progression of prostate cancer. Clinical Chemistry, 1998, 44, 705-723.	1.5	191
6	Mapping, genomic organization and promoter analysis of the human prostate-specific membrane antigen gene. Biochimica Et Biophysica Acta Gene Regulatory Mechanisms, 1998, 1443, 113-127.	2.4	163
7	THE ROLE OF NONLYMPHOID ACCESSORY CELLS IN THE IMMUNE RESPONSE TO DIFFERENT ANTIGENS. Journal of Experimental Medicine, 1970, 131, 461-482.	4.2	162
8	Emerging roles for phospholipase A2 enzymes in cancer. Biochimie, 2010, 92, 601-610.	1.3	160
9	THE SEPARATION OF DIFFERENT CELL CLASSES FROM LYMPHOID ORGANS. Journal of Cell Biology, 1971, 48, 566-579.	2.3	156
10	Macrophage inhibitory cytokine 1 reduces cell adhesion and induces apoptosis in prostate cancer cells. Cancer Research, 2003, 63, 5034-40.	0.4	136
11	The Propeptide Mediates Formation of Stromal Stores of PROMIC-1: Role in Determining Prostate Cancer Outcome. Cancer Research, 2005, 65, 2330-2336.	0.4	129
12	Purification and characterization of the 1.0 MDa CCR4-NOT complex identifies two novel components of the complex 1 1Edited by D. Draper. Journal of Molecular Biology, 2001, 314, 683-694.	2.0	128
13	Growth factor involvement in progression of prostate cancer. Clinical Chemistry, 1998, 44, 705-23.	1.5	127
14	Engineered silk fibroin protein 3D matrices for in vitro tumor model. Biomaterials, 2011, 32, 2149-2159.	5.7	126
15	CYCLOPHOSPHAMIDE TREATMENT OF RENAL DISEASE IN (NZB × NZW) F1 HYBRID MICE. Lancet, The, 1968, 291, 440-446.	6.3	114
16	MUC1, MUC2, MUC4, MUC5AC and MUC6 Expression in the Progression of Prostate Cancer. Clinical and Experimental Metastasis, 2005, 22, 565-573.	1.7	111
17	Prostate Specific Membrane Antigen Positron Emission Tomography May Improve the Diagnostic Accuracy of Multiparametric Magnetic Resonance Imaging in Localized Prostate Cancer. Journal of Urology, 2016, 196, 1261-1267.	0.2	109
18	Urokinase-type plasminogen activator and its receptor in colorectal cancer: Independent prognostic factors of metastasis and cancer-specific survival and potential therapeutic targets. International Journal of Cancer, 2000, 89, 431-439.	2.3	108

#	Article	IF	Citations
19	Co-expression of CD147 (EMMPRIN), CD44v3-10, MDR1 and monocarboxylate transporters is associated with prostate cancer drug resistance and progression. British Journal of Cancer, 2010, 103, 1008-1018.	2.9	106
20	Measurement of Serum Levels of Macrophage Inhibitory Cytokine 1 Combined with Prostate-Specific Antigen Improves Prostate Cancer Diagnosis. Clinical Cancer Research, 2006, 12, 89-96.	3.2	105
21	Cytosolic Phospholipase A2-Î±: A Potential Therapeutic Target for Prostate Cancer. Clinical Cancer Research, 2008, 14, 8070-8079.	3.2	98
22	Oncogenic Action of Secreted Phospholipase A2 in Prostate Cancer. Cancer Research, 2004, 64, 6934-6940.	0.4	97
23	A Tissue-Specific Enhancer of the Prostate-Specific Membrane Antigen Gene, FOLH1. Genomics, 2001, 73, 243-254.	1.3	96
24	Species-specific homing mechanisms of human prostate cancer metastasis in tissue engineered bone. Biomaterials, 2014, 35, 4108-4115.	5.7	95
25	Oncogenic action of phospholipase A2 in prostate cancer. Cancer Letters, 2006, 240, 9-16.	3.2	88
26	PSMA-targeting iron oxide magnetic nanoparticles enhance MRI of preclinical prostate cancer. Nanomedicine, 2015, 10, 375-386.	1.7	85
27	<i>In Vivo</i>Gene Therapy for Prostate Cancer: Preclinical Evaluation of Two Different Enzyme-Directed Prodrug Therapy Systems Delivered by Identical Adenovirus Vectors. Human Gene Therapy, 1998, 9, 1617-1626.	1.4	84
28	Induction of Immunity and Tolerance in vitro in the Absence of Phagocytic Cells. Nature, 1970, 225, 731-732.	13.7	83
29	3D Cultures of Prostate Cancer Cells Cultured in a Novel High-Throughput Culture Platform Are More Resistant to Chemotherapeutics Compared to Cells Cultured in Monolayer. PLoS ONE, 2014, 9, e111029.	1.1	79
30	Cytotoxic properties of immunoconjugates containing melittin-like peptide 101 against prostate cancer: in vitro and in vivo studies. Cancer Immunology, Immunotherapy, 2004, 53, 411-421.	2.0	78
31	Evaluation of urokinase plasminogen activator and its receptor in different grades of human prostate cancerâ˜†. Human Pathology, 2006, 37, 1442-1451.	1.1	77
32	PTRF/cavin-1 neutralizes non-caveolar caveolin-1 microdomains in prostate cancer. Oncogene, 2014, 33, 3561-3570.	2.6	72
33	Paraffin Section Storage and Immunohistochemistry. Applied Immunohistochemistry and Molecular Morphology, 2000, 8, 61-70.	0.6	72
34	Neuropilin-1 is upregulated in the adaptive response of prostate tumors to androgen-targeted therapies and is prognostic of metastatic progression and patient mortality. Oncogene, 2017, 36, 3417-3427.	2.6	68
35	Localised delivery of doxorubicin to prostate cancer cells through a PSMA-targeted hyperbranched polymer theranostic. Biomaterials, 2017, 141, 330-339.	5.7	68
36	Quantitative expression of protein markers of plasminogen activation system in prognosis of colorectal cancer. Journal of Surgical Oncology, 2003, 82, 184-193.	0.8	66

#	Article	IF	Citations
37	Preparation, DNA Binding, andin VitroCytotoxicity of a Pair of Enantiomeric Platinum(II) Complexes, [(R)- and (S)-3-Aminohexahydroazepine]dichloro- platinum(II). Crystal Structure of theSEnantiomer. Journal of Medicinal Chemistry, 1997, 40, 1090-1098.	2.9	65
38	Exosomes in Prostate Cancer: Putting Together the Pieces of a Puzzle. Cancers, 2013, 5, 1522-1544.	1.7	65
39	Tissue engineered humanized bone supports human hematopoiesisÂinÂvivo. Biomaterials, 2015, 61, 103-114.	5.7	62
40	Loss of KAI1 messenger RNA expression in both high-grade and invasive human bladder cancers. Clinical Cancer Research, 1997, 3, 1045-9.	3.2	62
41	Human Prostate Cancer Cell Lines. , 2003, 81, 21-40.		59
42	KAI1 tetraspanin and metastasis suppressor. International Journal of Biochemistry and Cell Biology, 2005, 37, 530-534.	1.2	59
43	Macrophage Inhibitory Cytokine-1 (MIC-1/GDF15) Slows Cancer Development but Increases Metastases in TRAMP Prostate Cancer Prone Mice. PLoS ONE, 2012, 7, e43833.	1.1	59
44	Clonal analysis of a bladder cancer cell line: an experimental model of tumour heterogeneity. British Journal of Cancer, 1990, 61, 369-376.	2.9	58
45	Gene therapy for prostate cancer delivered by ovine adenovirus and mediated by purine nucleoside phosphorylase and fludarabine in mouse models. Gene Therapy, 2002, 9, 759-768.	2.3	57
46	Concise review: Nanoparticles and cellular carriers-allies in cancer imaging and cellular gene therapy?. Stem Cells, 2010, 28, 1686-1702.	1.4	56
47	Paradoxical Roles of Tumour Necrosis Factor-Alpha in Prostate Cancer Biology. Prostate Cancer, 2012, 2012, 1-8.	0.4	55
48	Modulation of paracrine signaling by CD9 positive small extracellular vesicles mediates cellular growth of androgen deprived prostate cancer. Oncotarget, 2017, 8, 52237-52255.	0.8	55
49	Bladder cancer xenografts: a model of tumor cell heterogeneity. Cancer Research, 1986, 46, 2035-40.	0.4	55
50	Expression and regulation of MIM (Missing In Metastasis), a novel putative metastasis suppressor gene, and MIM-B, in bladder cancer cell lines. Cancer Letters, 2004, 215, 209-220.	3.2	54
51	Development of a polymer theranostic for prostate cancer. Polymer Chemistry, 2014, 5, 6932-6942.	1.9	53
52	Establishment and characterization of a new human bladder cancer cell line showing features of squamous and glandular differentiation. International Journal of Cancer, 1988, 41, 74-82.	2.3	52
53	Relationship between radiation response and p53 status in human bladder cancer cells. International Journal of Radiation Biology, 1997, 72, 11-20.	1.0	52
54	Relative activity and specificity of promoters from prostate-expressed genes. , 1998, 35, 18-26.		50

#	Article	IF	Citations
55	Postâ€translation modification of proteins in tears. Electrophoresis, 2010, 31, 1853-1861.	1.3	49
56	Methylation of a CpG island within the promoter region of the KAI1 metastasis suppressor gene is not responsible for down-regulation of KAI1 expression in invasive cancers or cancer cell lines. Cancer Letters, 2000, 157, 169-176.	3.2	48
57	Characterization of expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in prostate cancer cell lines. Prostate Cancer and Prostatic Diseases, 2003, 6, 15-26.	2.0	48
58	Alterations of p53 are common in early stage prostate cancer. Canadian Journal of Urology, 2003, 10, 1924-33.	0.0	48
59	Comparison between the clonogenic, MTT, and SRB assays for determining radiosensitivity in a panel of human bladder cancer cell lines and a ureteral cell line. Radiation Oncology Investigations, 1999, 7, 77-85.	1.3	47
60	Preparation, characterization, cytotoxicity, and mutagenicity of a pair of enantiomeric platinum(II) complexes with the potential to bind enantioselectively to DNA. Journal of Medicinal Chemistry, 1993, 36, 3663-3668.	2.9	46
61	Tryptic Digestion of In-Gel Proteins for Mass Spectrometry Analysis. Methods in Molecular Biology, 2009, 519, 507-513.	0.4	46
62	A novel model of boneâ€metastatic prostate cancer in immunocompetent Mice. Prostate, 2009, 69, 1613-1623.	1.2	45
63	Higher expression of oncoproteins c-myc, c-erbB-2/neu, PCNA, and p53 in metastasizing colorectal cancer than in nonmetastasizing tumors. Annals of Surgical Oncology, 1996, 3, 574-579.	0.7	44
64	Innovative biomarkers for prostate cancer early diagnosis and progression. Critical Reviews in Oncology/Hematology, 2010, 73, 10-22.	2.0	44
65	Is a Klebsiella plasmid involved in the aetiology of ankylosing spondylitis in HLA-b27-positive individuals?. Molecular Immunology, 1983, 20, 563-566.	1.0	42
66	Regulation of epidermal growth factor receptor in human colon cancer cell lines by interferon Â. Gut, 2004, 53, 123-129.	6.1	42
67	Gene-directed enzyme prodrug therapy for prostate cancer in a mouse model that imitates the development of human disease. Journal of Gene Medicine, 2004, 6, 43-54.	1.4	41
68	Humanised xenograft models of bone metastasis revisited: novel insights into species-specific mechanisms of cancer cell osteotropism. Cancer and Metastasis Reviews, 2013, 32, 129-145.	2.7	41
69	Title is missing!. Applied Immunohistochemistry & Molecular Morphology, 2000, 8, 61-70.	2.0	41
70	Diet-induced hypercholesterolemia promotes androgen-independent prostate cancer metastasis via IQGAP1 and caveolin-1. Oncotarget, 2015, 6, 7438-7453.	0.8	41
71	Studies of peritoneal macrophage function in mice with systemic lupus erythematosus: Depressed phagocytosis of opsonized sheep erythrocytes in vitro. Clinical Immunology and Immunopathology, 1983, 27, 387-402.	2.1	40
72	Antiproliferative effects of bacillus Calmette-Guï¿½rin and interferon ?2b on human bladder cancer cells in vitro. Cancer Immunology, Immunotherapy, 1995, 41, 309-316.	2.0	40

#	Article	IF	Citations
73	Modeling prostate cancer: a perspective on transgenic mouse models. Cancer and Metastasis Reviews, 2010, 29, 123-142.	2.7	40
74	IL-18 Inhibits Growth of Murine Orthotopic Prostate Carcinomas via Both Adaptive and Innate Immune Mechanisms. PLoS ONE, 2011, 6, e24241.	1.1	40
75	Protein Markers in Colorectal Cancer. Annals of Surgery, 1999, 230, 179.	2.1	40
76	Characterization of cell lines derived from a multiply aneuploid human bladder transitional-cell carcinoma, UCRU-BL-13. International Journal of Cancer, 1989, 44, 276-285.	2.3	38
77	Evaluation of Polymeric Nanomedicines Targeted to PSMA: Effect of Ligand on Targeting Efficiency. Biomacromolecules, 2015, 16, 3235-3247.	2.6	38
78	CHANGES IN EPIDERMAL GROWTH FACTOR RECEPTOR EXPRESSION IN HUMAN BLADDER CANCER CELL LINES FOLLOWING INTERFERON-Î± TREATMENT. Journal of Urology, 2004, 172, 733-738.	0.2	37
79	Clinical pharmacology of isoflavones and its relevance for potential prevention of prostate cancer. Nutrition Reviews, 2010, 68, 542-555.	2.6	37
80	Characterization of Mutations in NOT2 Indicates that it Plays an Important Role in Maintaining the Integrity of the CCR4â€"NOT Complex. Journal of Molecular Biology, 2002, 322, 27-39.	2.0	36
81	Detection of Malignant Cells in Voided Urine from Patients with Bladder Cancer, A Novel Monoclonal Assay. Journal of Urology, 1989, 142, 1578-1583.	0.2	35
82	Flow cytometric and karyotypic analysis of a primary small cell carcinoma of the prostate: A xenografted cell line. Cancer Genetics and Cytogenetics, 1987, 26, 165-169.	1.0	34
83	Preparation, Characterization, DNA Binding, and in Vitro Cytotoxicity of the Enantiomers of the Platinum(II) Complexes N-Methyl-, N-Ethyl- and N,N-Dimethyl-(R)- and -(S)-3-aminohexahydroazepinedichloroplatinum(II). Journal of Medicinal Chemistry, 1997, 40, 3508-3515.	2.9	34
84	Combination of cytosine deaminase with uracil phosphoribosyl transferase leads to local and distant bystander effects against RM1 prostate cancer in mice. Journal of Gene Medicine, 2006, 8, 1086-1096.	1.4	34
85	The role of extracellular matrix metalloproteinase inducer protein in prostate cancer progression. Cancer Immunology, Immunotherapy, 2008, 57, 1367-1379.	2.0	34
86	Label-free isolation of a prostate cancer cell among blood cells and the single-cell measurement of drug accumulation using an integrated microfluidic chip. Biomicrofluidics, 2015, 9, 064104.	1.2	34
87	Caffeine-increased radiosensitivity is not dependent on a loss of G2/M arrest or apoptosis in bladder cancer cell lines. International Journal of Radiation Biology, 1999, 75, 481-492.	1.0	33
88	Genetic Markers of Survival and Liver Recurrence after Resection of Liver Metastases from Colorectal Cancer. World Journal of Surgery, 2001, 25, 996-1001.	0.8	33
89	Expression of HER1/EGFR protein in human soft tissue sarcomas. European Journal of Surgical Oncology, 2006, 32, 466-468.	0.5	33
90	Molecular profiling of bladder cancer: Involvement of the TGF-Î² pathway in bladder cancer progression. Cancer Letters, 2008, 265, 27-38.	3.2	33

#	Article	IF	Citations
91	Relative efficiency of tumor cell killing in vitro by two enzyme-prodrug systems delivered by identical adenovirus vectors. Clinical Cancer Research, 1997, 3, 2075-80.	3.2	33
92	Establishing prostate cancer patient derived xenografts: Lessons learned from older studies. Prostate, 2015, 75, 628-636.	1.2	32
93	Mutations within the tumour suppressor gene p53 are not confined to a late event in prostate cancer progression. Urologic Oncology: Seminars and Original Investigations, 2001, 6, 103-110.	0.8	31
94	Purine nucleoside phosphorylase and fludarabine phosphate gene-directed enzyme prodrug therapy suppresses primary tumour growth and pseudo-metastases in a mouse model of prostate cancer. Journal of Gene Medicine, 2004, 6, 1343-1357.	1.4	31
95	Down-regulation of KAI1/CD82 protein expression in oral cancer correlates with reduced disease free survival and overall patient survival. Cancer Letters, 2004, 213, 91-98.	3.2	31
96	Ectopic hormone production by a prostatic small cell carcinoma xenograft line. Molecular and Cellular Endocrinology, 1988, 55, 167-172.	1.6	30
97	Genomic alterations (LOH, MI) on chromosome 17q21-23 and prognosis of sporadic colorectal cancer. International Journal of Cancer, 2000, 89, 1-7.	2.3	30
98	Inverse correlation between KAI1 mRNA levels and invasive behaviour in bladder cancer cell lines. Cancer Letters, 2000, 156, 9-17.	3.2	30
99	Transcription-targeted gene therapy for androgen-independent prostate cancer. Cancer Gene Therapy, 2002, 9, 443-452.	2.2	30
100	Preclinical evaluation of a prostate-targeted gene-directed enzyme prodrug therapy delivered by ovine atadenovirus. Gene Therapy, 2004, 11, 1559-1567.	2.3	30
101	Multifunctional coreâ€“shell magnetic cisplatin nanocarriers. Chemical Communications, 2009, , 7348.	2.2	30
102	Relationship between expression of the KAI1 metastasis suppressor and other markers of advanced bladder cancer. , 2000, 191, 39-47.		29
103	Zoledronic Acid Preserves Bone Structure and Increases Survival but Does Not Limit Tumour Incidence in a Prostate Cancer Bone Metastasis Model. PLoS ONE, 2011, 6, e19389.	1.1	28
104	Using prostate specific membrane antigen (PSMA) expression in clear cell renal cell carcinoma for imaging advanced disease. Pathology, 2016, 48, 613-616.	0.3	27
105	Derivation of MPR and TRAMP models of prostate cancer and prostate cancer metastasis for evaluation of therapeutic strategies. Urologic Oncology: Seminars and Original Investigations, 2002, 7, 111-118.	0.8	26
106	Gamma-Tocotrienol Induces Apoptosis in Prostate Cancer Cells by Targeting the Ang-1/Tie-2 Signalling Pathway. International Journal of Molecular Sciences, 2019, 20, 1164.	1.8	26
107	Growth and metastasis of human bladder cancer xenografts in the bladder of nude rats. Urological Research, 1991, 19, 207-213.	1.5	25
108	Analysis of expressed N-ras mutations in human melanoma short-term cell lines with allele specific restriction analysis induced by the polymerase chain reaction. European Journal of Cancer, 1992, 28, 9-11.	1.3	25

#	Article	IF	Citations
109	Targeted Î±-therapy for control of micrometastatic prostate cancer. Expert Review of Anticancer Therapy, 2004, 4, 459-468.	1.1	25
110	Promising tumorâ€associated antigens for future prostate cancer therapy. Medicinal Research Reviews, 2010, 30, 67-101.	5.0	25
111	Macrophage Inhibitory Cytokine-1 (MIC-1/GDF15) Gene Deletion Promotes Cancer Growth in TRAMP Prostate Cancer Prone Mice. PLoS ONE, 2015, 10, e0115189.	1.1	25
112	Inhibition of Micrometastatic Prostate Cancer Cell Spread in Animal Models By 213Bilabeled Multiple Targeted Î± Radioimmunoconjugates. Clinical Cancer Research, 2009, 15, 865-875.	3.2	24
113	Adipocytes promote prostate cancer stem cell self-renewal through amplification of the cholecystokinin autocrine loop. Oncotarget, 2016, 7, 4939-4948.	0.8	24
114	Overexpression of nm23 Protein Assessed by Color Video Image Analysis in Metastatic Colorectal Cancer: Correlation with Reduced Patient Survival. World Journal of Surgery, 1998, 22, 484-490.	0.8	22
115	Molecular and traditional chemotherapy: A united front against prostate cancer. Cancer Letters, 2010, 293, 1-14.	3.2	22
116	Extracellular vesicles for personalized therapy decision support in advanced metastatic cancers and its potential impact for prostate cancer. Prostate, 2017, 77, 1416-1423.	1.2	22
117	Site-specific growth of the prostate xenograft line UCRU-PR-2. Prostate, 1989, 14, 163-175.	1.2	21
118	Molecular Biology of Urological Tumours. British Journal of Urology, 1990, 65, 121-130.	0.1	21
119	Relationship between expression of KAI1 metastasis suppressor gene, mRNA levels and p53 in human bladder and prostate cancer cell lines. Urologic Oncology: Seminars and Original Investigations, 2002, 7, 99-104.	0.8	21
120	Antigenic expression of human metastatic prostate cancer cell lines for in vitro multiple-targeted Î±-therapy with 213Bi-conjugates. International Journal of Radiation Oncology Biology Physics, 2004, 60, 896-908.	0.4	21
121	Tie-2 regulates the stemness and metastatic properties of prostate cancer cells. Oncotarget, 2016, 7, 2572-2584.	0.8	21
122	Failure Ofklebsiella pneumoniae antibodies to cross-react with peripheral blood mononuclear cells from patients with ankylosing spondylitis. Arthritis and Rheumatism, 1987, 30, 300-305.	6.7	20
123	Detection of a rare point mutation in Ki-ras of a human bladder cancer xenograft by polymerase chain reaction and direct sequencing. Urological Research, 1992, 20, 121-126.	1.5	20
124	Increased targeting of adenine-rich sequences by (2-amino-2-methyl-3-butanone) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 147 Td (oxime)di Inorganic Chemistry, 2000, 5, 675-681.	1.1	20
125	Downregulation of KAI1 mRNA in localised prostate cancer and its bony metastases does not correlate with p53 overexpression. Prostate Cancer and Prostatic Diseases, 2003, 6, 174-181.	2.0	20
126	Biodistributions of intact monoclonal antibodies and fragments of BLCA-38, a new prostate cancer directed antibody. Cancer Immunology, Immunotherapy, 2004, 53, 533-542.	2.0	20

#	Article	IF	Citations
127	Immunohistochemical characterisation of the monoclonal antibody BLCA-38 for the detection of prostate cancer. Cancer Immunology, Immunotherapy, 2004, 53, 995-1004.	2.0	20
128	Preparation and testing of bevacizumab radioimmunoconjugates with Bismuth-213 and Bismuth-205 / Bismuth-206. Cancer Biology and Therapy, 2008, 7, 1547-1554.	1.5	20
129	Tumour-induced host stromal-cell transformation: Induction of mouse spindle-cell fibrosarcoma not mediated by gene transfer. International Journal of Cancer, 1990, 46, 299-309.	2.3	19
130	Role of the Akt Pathway in Prostate Cancer. Current Cancer Drug Targets, 2009, 9, 163-175.	0.8	19
131	Elastase activities of human bladder cancer cell lines derived from high grade invasive tumours. Biochemical and Biophysical Research Communications, 1989, 162, 308-315.	1.0	18
132	Characterization of a New Human Bladder Cancer Cell Line, Ucru-BL-28. Journal of Urology, 1993, 150, 1038-1044.	0.2	18
133	Application of in-gel protease assay in a biological sample: Characterization and identification of urokinase-type plasminogen activator (uPA) in secreted proteins from a prostate cancer cell line PC-3. Electrophoresis, 2004, 25, 1142-1148.	1.3	18
134	Control of prostate cancer spheroid growth using 213 Bi-labeled multiple targeted Î± radioimmunoconjugates. Prostate, 2006, 66, 1753-1767.	1.2	18
135	From Bench to Bedside: Immunotherapy for Prostate Cancer. BioMed Research International, 2014, 2014, 1-11.	0.9	18
136	Targeted beta therapy of prostate cancer with 177Lu-labelled MiltuximabÂ® antibody against glypican-1 (GPC-1). EJNMMI Research, 2020, 10, 46.	1.1	18
137	Features of squamous and adenocarcinoma in the same cell in a xenografted human transitional cell carcinoma: Evidence of a common histogenesis?. Urological Research, 1988, 16, 79-84.	1.5	17
138	Application of the transgenic adenocarcinoma mouse prostate (TRAMP) model for pre-clinical therapeutic studies. Anticancer Research, 2003, 23, 2633-42.	0.5	17
139	Trypsin activity assay in substrate-specific one- and two-dimensional gels: A powerful method to separate and characterize novel proteases in active form in biological samples. Electrophoresis, 2003, 24, 3284-3288.	1.3	16
140	Radiotherapy in Larynx Squamous Cell Carcinoma is not Associated with an Increased Diagnosis of Second Primary Tumours. Clinical Oncology, 2009, 21, 315-319.	0.6	16
141	Ectopic hormone production by small cell undifferentiated carcinomas. Molecular and Cellular Endocrinology, 1990, 71, 1-12.	1.6	15
142	Expression of insulin-like growth factor mitogenic signals in adult soft-tissue sarcomas: significant correlation with malignant potential. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2004, 444, 142-148.	1.4	15
143	Interferon-Î± Promotes the Anti-Proliferative Effect of Gefitinib (ZD1839) on Human Colon Cancer Cell Lines. Oncology, 2005, 69, 224-238.	0.9	15
144	Novel gene-directed enzyme prodrug therapies against prostate cancer. Expert Opinion on Investigational Drugs, 2006, 15, 947-961.	1.9	15

#	Article	IF	Citations
145	Erlotinib (OSI-774)-induced inhibition of transitional cell carcinoma of bladder cell line growth is enhanced by interferon-?. BJU International, 2007, 99, 1539-1545.	1.3	15
146	Diagnosis of second head and neck tumors in primary laryngeal SCC is an indicator of overall survival and not associated with poorer overall survival: A single centre study in 987 patients. Journal of Surgical Oncology, 2010, 101, 72-77.	0.8	15
147	Humanization of the Prostate Microenvironment Reduces Homing of PC3 Prostate Cancer Cells to Human Tissue-Engineered Bone. Cancers, 2018, 10, 438.	1.7	15
148	Evidence for post-transcriptional down-regulation of the apoptosis-related genebcl-2 in human colorectal cancer. , 2000, 191, 15-20.		14
149	Over-expression of p53 mutants in LNCaP cells alters tumor growth and angiogenesis in vivo. Biochemical and Biophysical Research Communications, 2006, 345, 1207-1214.	1.0	14
150	Molecular Chemotherapy and Chemotherapy: A New Front against Late-Stage Hormone-Refractory Prostate Cancer. Clinical Cancer Research, 2011, 17, 4006-4018.	3.2	14
151	An inverse relationship between KAI1 expression, invasive ability, and MMP-2 expression and activity in bladder cancer cell lines. Urologic Oncology: Seminars and Original Investigations, 2012, 30, 502-508.	0.8	14
152	Elevated levels of prostate-specific antigen (PSA) in prostate cancer cells expressing mutant p53 is associated with tumor metastasis. Molecular Carcinogenesis, 2003, 38, 130-140.	1.3	13
153	Interferon-alpha promotes the anti-proliferative effect of Erlotinib (OSI-774) on human colon cancer cell lines. Cancer Letters, 2005, 225, 61-74.	3.2	13
154	Paclitaxel suppresses the growth of primary prostate tumours (RM-1) and metastases in the lung in C57BL/6 mice. Cancer Letters, 2006, 233, 185-191.	3.2	13
155	Paclitaxel enhanced radiation sensitization for the suppression of human prostate cancer tumor growth via a p53 independent pathway. Prostate, 2007, 67, 1630-1640.	1.2	13
156	Heterogeneity of in vitro radiosensitivity in human bladder cancer cells. Radiation Oncology Investigations, 1999, 7, 66-76.	1.3	12
157	Animal Models of Prostate Cancer. , 2003, 81, 89-112.		12
158	Cytosine Deaminase-Uracil Phosphoribosyltransferase and Interleukin (IL)-12 and IL-18: A Multimodal Anticancer Interface Marked by Specific Modulation in Serum Cytokines. Clinical Cancer Research, 2009, 15, 2323-2334.	3.2	12
159	Purine Nucleoside Phosphorylase mediated molecular chemotherapy and conventional chemotherapy: A tangible union against chemoresistant cancer. BMC Cancer, 2011, 11, 368.	1.1	12
160	Extracellular Vesicles in the Adaptive Process of Prostate Cancer during Inhibition of Androgen Receptor Signaling by Enzalutamide. Proteomics, 2017, 17, 1600427.	1.3	12
161	Human Group IIA Phospholipase A2â€"Three Decades on from Its Discovery. Molecules, 2021, 26, 7267.	1.7	12
162	Broadening of transgenic adenocarcinoma of the mouse prostate (TRAMP) model to represent late stage androgen depletion independent cancer. Prostate, 2008, 68, 548-562.	1.2	11

#	Article	IF	Citations
163	Radiotherapy is not associated with an increased rate of Second Primary Tumours in Oral Squamous Carcinoma: A study of 370 patients. Oral Oncology, 2009, 45, 941-945.	0.8	11
164	Protein Expression of Epidermal Growth Factor Receptor in Laryngeal Squamous Cell Carcinoma Index Tumors Correlates with Diagnosis of Second Primary Tumors of the Upper Aero-Digestive Tract. Annals of Surgical Oncology, 2009, 16, 2888-2894.	0.7	11
165	Stability of lectin binding properties expressed by human bladder carcinoma cell lines passaged in vitro or in nude mice. Urological Research, 1988, 16, 407-414.	1.5	10
166	Studies of autologous mixed lymphocyte reactions in patients with systemic lupus erythematosus. Pathology, 1983, 15, 37-43.	0.3	10
167	Studies of Macrophage Function in Murine Systemic Lupus Erythematosus. 3. The Nature, Anatomical Location, and Reversibility of the Phagocytic Defect. Journal of Leukocyte Biology, 1986, 39, 49-62.	1.5	9
168	The Use of Monoclonal Antibodies for the Diagnosis and Therapy of Bladder Cancer. British Journal of Urology, 1993, 71, 121-129.	0.1	9
169	Murine CTLL-2 cells respond to mIL12: Prospects for developing an alternative bioassay for measurement of murine cytokines IL12 and IL18. Journal of Immunological Methods, 2007, 326, 41-53.	0.6	9
170	Mutant p53 and cyclin A1 protein expression in primary laryngeal squamous cell carcinomas do not correlate to second primary tumours of the head and neck*. ANZ Journal of Surgery, 2009, 79, 48-54.	0.3	9
171	Absolute quantification of human tear lactoferrin using multiple reaction monitoring technique with stable-isotopic labeling. Analytical Biochemistry, 2016, 496, 30-34.	1.1	9
172	In vivo overexpression of c-erbB-2 oncoprotein in xenografts of mice implanted with human colon cancer lines. Anticancer Research, 1997, 17, 3463-8.	0.5	9
173	Elevated expression of FGF-2 does not cause prostate cancer progression in LNCaP cells. , 1999, 40, 1-13.		8
174	Expression of steroid hormone receptors in BRCA1-associated ovarian carcinomas. Gynecologic Oncology, 2005, 97, 16-25.	0.6	8
175	The prognostic significance of tumor-associated markers p53, HER-2/neu, c-myc, v-H-ras, PCNA and EGFr of local and distant recurrence in localized human prostatic adenocarcinoma. Urologic Oncology: Seminars and Original Investigations, 1995, 1, 144-152.	0.8	7
176	Plant-Derived MINA-05 Inhibits Human Prostate Cancer Proliferation In Vitro and Lymph Node Spread In Vivo. Neoplasia, 2007, 9, 322-331.	2.3	7
177	Studies of Peritoneal Macrophage Function in Murine Systemic Lupus Erythematosus. 2. Nature of Elevated Resident Peritoneal Cells in NZB and (NZB Ã— NZW)F1 Mice. Journal of Leukocyte Biology, 1985, 38, 241-254.	1.5	6
178	Antigenic Variation and Macrophage Infiltration of Human Bladder Tumors Xenografted Into Nude Mice. Journal of Leukocyte Biology, 1988, 43, 335-342.	1.5	6
179	Detection of tumor-associated membrane proteins in prostate and bladder carcinomas by means of protein blotting. Urological Research, 1989, 17, 305-10.	1.5	6
180	Monoclonal antibodies for intravesical radioimmunotherapy of human bladder cancer. Cell Biophysics, 1993, 22, 27-47.	0.4	6

#	Article	IF	Citations
181	No differences in p53 mutation frequencies between BRCA1-associated and sporadic ovarian cancers. Gynecologic Oncology, 2004, 95, 430-436.	0.6	6
182	Alterations to the protein profile of bladder carcinoma cell lines induced by plant extract MINAâ€•05 <i>in vitro</i>. Proteomics, 2009, 9, 1883-1892.	1.3	6
183	Preclinical studies of monoclonal antibodies for intravesical radioimmunotherapy of human bladder cancer. Cell Biophysics, 1994, 24-25, 155-161.	0.4	5
184	Reliable Method of Isolating Transfected Clones from the LNCaP Human Prostatic Cell Line. BioTechniques, 1997, 23, 66-70.	0.8	5
185	Targeting Aurora Kinases: A Novel Approach to Curb the Growth & Chemoresistance of Androgen Refractory Prostate Cancer. Current Cancer Drug Targets, 2012, 12, 144-163.	0.8	5
186	KLK4 Induces Anti-Tumor Effects in Human Xenograft Mouse Models of Orthotopic and Metastatic Prostate Cancer. Cancers, 2020, 12, 3501.	1.7	5
187	A humanized orthotopic tumor microenvironment alters the bone metastatic tropism of prostate cancer cells. Communications Biology, 2021, 4, 1014.	2.0	5
188	Studies of X-irradiated bladder cancer cell lines showing differences in p53 status: absence of a p53-dependent cell cycle checkpoint pathway. Oncogene, 1996, 13, 1269-78.	2.6	5
189	Experimental models of histogenesis and tumor cell heterogeneity in bladder cancer. Journal of Surgical Oncology, 1992, 8, 279-284.	1.4	4
190	Karyotypic analysis of a heterogeneous human transitional cell carcinoma of the bladder. Cancer Genetics and Cytogenetics, 1994, 72, 116-125.	1.0	4
191	DNA flow-cytometric analysis in colorectal cancer: A comparison of metastasizing and non-metastasizing tumours. Journal of Gastroenterology and Hepatology (Australia), 1996, 11, 319-324.	1.4	4
192	Antiproliferative effects of bacillus Calmette-Guï¿½rin and interferon ?2b on human bladder cancer cells in vitro. Cancer Immunology, Immunotherapy, 1995, 41, 309-316.	2.0	4
193	Active and pro-plasminogen activator on the surface of human bladder cancer cells derived from a high grade invasive tumour. Biochemical and Biophysical Research Communications, 1990, 172, 870-876.	1.0	3
194	Second Primary Tumours of the Head and Neck are not Associated ith Adverse Overall Survival in Oral Sccs. Journal of Cancer Science & Therapy, 2011, 03, .	1.7	3
195	DNA-Flow Cytometric Analysis of Bladder TCC Using Paraffin-Embedded Tissues. Urologia Internationalis, 1998, 60, 208-215.	0.6	2
196	Transduction of Biopsy Samples: Bridging Gene Therapy between Animals and Humans. BioTechniques, 2001, 31, 46-49.	0.8	2
197	Androgen decreases osteoprotegerin expression in prostate cancer cells. Prostate Cancer and Prostatic Diseases, 2007, 10, 160-166.	2.0	2
198	In Vitro Assessment of Migratory Behavior of Two Cell Populations in a Simple Multichannel Microdevice. Processes, 2013, 1, 349-359.	1.3	2

#	Article	IF	Citations
199	Electron microscopy of renal glomerular basement membrane changes in healthy mice and in spontaneous and nephrotoxic murine nephritis. Pathology, 1969, 1, 167-175.	0.3	2
200	Studies of macrophage function in murine systemic lupus erythematosus. 4. failure to reverse the defect in fc-mediated phagocytosis and binding by in vitro stimulants or prostaglandins. Pathology, 1986, 18, 59-63.	0.3	2
201	Targeted Alpha Therapy of Prostate Cancer. , 2003, 81, 333-358.		1
202	An investigation of fludarabine as a potential radiation sensitizer of human prostate cancer cells in vitro. Asia-Pacific Journal of Clinical Oncology, 2008, 4, 48-54.	0.7	1
203	Drug Accumulation Into Single Drug-Sensitive and Drug-Resistant Prostate Cancer Cells Conducted on the Single Cell Bioanalyzer. , 2014, , .		1
204	Characterisation of the anti-bladder-cancer monoclonal antibody BLCA-8: Identification of its antigen as a neutral glycolipid. Cancer Immunology, Immunotherapy, 1995, 41, 348-354.	2.0	0
205	HN03Ã¯Â¿Â½HEAD AND NECK SECOND PRIMARY TUMORS IN LARYNGEAL SCC ARE NOT ASSOCIATED WITH POORER OVERALL SURVIVAL: A SINGLE CENTER STUDY IN 987 PATIENTS. ANZ Journal of Surgery, 2009, 79, A37-A37.	0.3	0
206	BRCA1 mutation site may associate with nuclear DNA content in BRCA1-associated ovarian carcinomas. Journal of Clinical Oncology, 2004, 22, 5040-5040.	0.8	0
207	Active Protease Mapping in 2DE Gels. Methods in Molecular Biology, 2009, 519, 431-438.	0.4	0
208	Abstract C30: Use of targeted magnetic nanoparticles for imaging in prostate cancer. Cancer Research, 2012, 72, C30-C30.	0.4	0
209	<i>BRCA1</i> mutation site may associate with nuclear DNA content in <i>BRCA1</i>-associated ovarian carcinomas. Journal of Clinical Oncology, 2004, 22, 5040-5040.	0.8	0